Aliases & Classifications for Reading Disorder

MalaCards integrated aliases for Reading Disorder:

Name: Reading Disorder 12 14
Developmental Reading Disorder 69
Specific Reading Disorder 69
Dyslexia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13365
ICD9CM 35 315.09
ICD10 33 F81.0
UMLS 69 C0154631

Summaries for Reading Disorder

Disease Ontology : 12 A learning disability involing difficulty reading resulting primarily from neurological factors which affect any part of the reading process.

MalaCards based summary : Reading Disorder, also known as developmental reading disorder, is related to dyslexia and rahman syndrome, and has symptoms including aprosodia An important gene associated with Reading Disorder is SLITRK2 (SLIT And NTRK Like Family Member 2). The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart.

Related Diseases for Reading Disorder

Graphical network of the top 20 diseases related to Reading Disorder:



Diseases related to Reading Disorder

Symptoms & Phenotypes for Reading Disorder

UMLS symptoms related to Reading Disorder:


aprosodia

Drugs & Therapeutics for Reading Disorder

Drugs for Reading Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 615)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4 59-92-7 6047
3
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
4
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
5
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
6
Ephedrine Approved Phase 4 299-42-3 9294
7
Pseudoephedrine Approved Phase 4 90-82-4 7028
8
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
9
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
10
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
11
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
12
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
13
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
14
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
15
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
16
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
17
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
18
Timolol Approved Phase 4 26839-75-8 33624 5478
19
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
20
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
21
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
22
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
23
Insulin Aspart Approved Phase 4,Phase 2 116094-23-6 16132418
24
Insulin Glargine Approved Phase 4 160337-95-1
25
Insulin Lispro Approved Phase 4,Phase 2 133107-64-9
26
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
27
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
28
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
29
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
30
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
32
Etanercept Approved, Investigational Phase 4,Phase 3 185243-69-0
33
Doxazosin Approved Phase 4 74191-85-8 3157
34
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
35
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
36
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
37
Carbidopa Approved Phase 4 28860-95-9 34359 38101
38
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
40
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
41
Dinoprost Investigational Phase 4 551-11-1 5283078
42 Antiparkinson Agents Phase 4
43 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Dopamine agonists Phase 4,Phase 2,Phase 3
46 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
48 Protective Agents Phase 4,Phase 3,Phase 2
49 Anabolic Agents Phase 4,Phase 3
50 Androgens Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 1114)

id Name Status NCT ID Phase Drugs
1 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4 Levodopa
2 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
4 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
5 Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia Completed NCT00716274 Phase 4 Atomoxetine;Placebo
6 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4 Methylphenidate;Mixed Salt Amphetamine;Atomoxetine;Guanfacine
7 Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Completed NCT00607919 Phase 4 Atomoxetine;Placebo
8 Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Completed NCT00191048 Phase 4 Atomoxetine
9 The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading Completed NCT00733356 Phase 4 Vyvanse
10 A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pul Completed NCT02982187 Phase 4
11 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4 Bimatoprost;Eye drop solution
12 Cost-Effectiveness Study Of The Treatment Of Attention Deficit/Hyperactivity Disorder In Brazil Completed NCT01228604 Phase 4 methylphenidate (Ritalin®)
13 Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease Completed NCT01183845 Phase 4
14 Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices Completed NCT02184624 Phase 4
15 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
16 Evaluation of Reader Training Processes Completed NCT02051790 Phase 4 florbetapir F 18
17 Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease Completed NCT01026389 Phase 4 Dotarem;Gadovist
18 Omega 3/6 Fatty Acids for Reading in Children Completed NCT02557477 Phase 4
19 The Feasibility of Florbetapir Quantitation in Europe Completed NCT02107599 Phase 4 Florbetapir (18F)
20 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy Completed NCT02802137 Phase 4 tafluprost;tafluprost and dorzolamide/timolol
21 Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction Completed NCT00720005 Phase 4
22 Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD). Completed NCT00404261 Phase 4 Fluticasone/Salmeterol HFA
23 The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD Completed NCT02501798 Phase 4 Methylphenidate;Placebo
24 Trial of Comprehensive Migraine Intervention Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
25 Effects of Interactive Video Game Cycling on Obese Adolescent Health Completed NCT00983970 Phase 4
26 The Whole Day First Grade Program Completed NCT00257088 Phase 4
27 Cognitive Skills Training Using Computer for Patients With Severe Mental Illness Completed NCT01036282 Phase 4
28 A Phase IV Study of Cipro XR in Uncomplicated UTI Completed NCT00663806 Phase 4
29 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
30 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed NCT01524705 Phase 4 "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)];Insulin glargine, metformin, prandial insulin
31 CONCERTA Lab School Study Completed NCT00799487 Phase 4 CONCERTA (methylphenidate HCl) or placebo;CONCERTA (methylphenidate HCl) or placebo
32 Lab School Day Study for CONCERTA of Older Children With ADHD Completed NCT00799409 Phase 4 Placebo/ CONCERTA (methylphenidate HCl);CONCERTA (methylphenidate HCl) / Placebo
33 Bipolar Study in Adults at Least 18 Years of Age Completed NCT00067938 Phase 4 lamotrigine
34 Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD Completed NCT02161575 Phase 4 Ranibizumab
35 Salt Loading and Thiazide Intervention Study Completed NCT00896389 Phase 4 Hydrochlorothiazide (HCTZ)
36 Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes Completed NCT01409239 Phase 4 Intravenous insulin;Subcutaneous Insulin
37 Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma Completed NCT00995657 Phase 4 Fluticasone Propionate;Fluticasone Propionate
38 Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program Completed NCT00401726 Phase 4 Venlafaxine ER
39 The Jetstream (JET) Post-market Registry Completed NCT01436435 Phase 4
40 Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient Completed NCT01277250 Phase 4
41 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4 Cyclosporine 0.05% Ophthalmic Emulsion
42 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4 cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
43 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Completed NCT00327418 Phase 4 Atorvastatin
44 A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed NCT01331837 Phase 4 Etanercept;Tocilizumab
45 Japan Morning Surge-1 Study Completed NCT00285519 Phase 4 Doxazosin (drug)
46 Effect of Antenatal Steroid on Pulmonary Artery Blood Flow Recruiting NCT02978976 Phase 4 Betamethasone;saline
47 Curarisation and Intubation Conditions During Videolaryngoscopy With Glidescope Titanium Recruiting NCT02404142 Phase 4 Curare (Atracurium);saline isotonic solution
48 Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluid During Renal Transplantation Recruiting NCT03115060 Phase 4 intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
49 INfusion VErsus STimulation in Parkinson's Disease Recruiting NCT02480803 Phase 4 Continuous intrajejunal infusion of levodopa-carbidopa
50 VITAL - Individualising Therapy for Neovascular AMD With Aflibercept Active, not recruiting NCT02441816 Phase 4 Aflibercept

Search NIH Clinical Center for Reading Disorder

Genetic Tests for Reading Disorder

Anatomical Context for Reading Disorder

MalaCards organs/tissues related to Reading Disorder:

39
Brain, Testes, Heart, Lung, Eye, Colon, Bone

Publications for Reading Disorder

Articles related to Reading Disorder:

(show all 42)
id Title Authors Year
1
Possible roles for fronto-striatal circuits in reading disorder. ( 27826071 )
2017
2
Neurobiological bases of reading disorder Part I: Etiological investigations. ( 28785303 )
2017
3
Descriptive epidemiology of prenatal and perinatal risk factors in a Chinese population with reading disorder. ( 27819320 )
2016
4
Comorbidity of Arithmetic and Reading Disorder: Basic Number Processing and Calculation in Children With Learning Impairments. ( 26772796 )
2016
5
Lifelong Reading Disorder and Mild Cognitive Impairment: Implications for Diagnosis. ( 26639959 )
2015
6
Effectiveness of EEG-Biofeedback on Attentiveness, Working Memory and Quantitative Electroencephalography on Reading Disorder. ( 24644508 )
2013
7
Commentary: translating quantitative genetics into molecular genetics: decoupling reading disorder and ADHD - reflections on Greven et al. and Rosenberg et al. (2012). ( 22260725 )
2012
8
The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden. ( 21757683 )
2012
9
Language Impairments in Children With ADHD and in Children With Reading Disorder. ( 23074303 )
2012
10
Patient characteristics, comorbidities, and medication use for children with ADHD with and without a co-occurring reading disorder: A retrospective cohort study. ( 22145783 )
2011
11
The influence of working memory load on response inhibition in children with attention-deficit/hyperactivity disorder or reading disorder. ( 21432708 )
2011
12
Tourette syndrome and reading disorder in a boy with left parietofrontal tract disruption. ( 22019420 )
2011
13
Processing speed and working memory performance in those with both ADHD and a reading disorder compared with those with ADHD alone. ( 21613301 )
2011
14
Working memory, response inhibition, and within-subject variability in children with attention-deficit/hyperactivity disorder or reading disorder. ( 19813130 )
2010
15
Amblyopic dyslexia: a little investigated reading disorder. ( 20401806 )
2010
16
Error monitoring in children with ADHD or reading disorder: An event-related potential study. ( 20097256 )
2010
17
Evidence for specificity of ERP abnormalities during response inhibition in ADHD children: a comparison with reading disorder children without ADHD. ( 19850394 )
2010
18
Reading disorders in primary progressive aphasia: a behavioral and neuroimaging study. ( 19428421 )
2009
19
Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder. ( 20035588 )
2009
20
Expressive versus receptive language skills in specific reading disorder. ( 18415729 )
2008
21
Detection of simulated ADHD and reading disorder using symptom validity measures. ( 18534813 )
2008
22
Mismatch negativity (MMN) elicited by duration deviations in children with reading disorder, attention deficit or both. ( 18440662 )
2008
23
The relationship between attention, executive functions and reading domain abilities in attention deficit hyperactivity disorder and reading disorder: a comparative study. ( 17501726 )
2007
24
Error-related event-related potentials in children with attention-deficit hyperactivity disorder, oppositional defiant disorder, reading disorder, and math disorder. ( 17257731 )
2007
25
Children with reading disorder show modality independent brain abnormalities during semantic tasks. ( 17010394 )
2007
26
Electrophysiological and behavioral evidence of auditory processing deficits in children with reading disorder. ( 16564738 )
2006
27
Maternal stress in nonverbal learning disorder: a comparison with reading disorder. ( 16724792 )
2006
28
Meta-analysis of the nonword reading deficit in specific reading disorder. ( 17009769 )
2006
29
A stimulus-centered reading disorder for words and numbers: Is it neglect dyslexia? ( 16393754 )
2005
30
Spatial-frequency- and contrast-dependent visible persistence and reading disorder: no evidence for a basic perceptual deficit. ( 15206008 )
2004
31
JAMA patient page. Reading disorder. ( 15113824 )
2004
32
Alexia and related reading disorders. ( 12916491 )
2003
33
Executive functioning deficits in attention-deficit/hyperactivity disorder are independent of oppositional defiant or reading disorder. ( 10504814 )
1999
34
Varieties of developmental reading disorder: genetic and environmental influences. ( 9927524 )
1999
35
Language and memory in children with combined complex-partial epilepsy and reading disorder. ( 8323126 )
1993
36
Developmental reading disorder: predictors of outcome in adolescents who received early diagnosis and treatment. ( 1469107 )
1992
37
A comparison of 13-year-old boys with attention deficit and/or reading disorder on neuropsychological measures. ( 2926022 )
1989
38
Language mechanisms and reading disorder: a modular approach. ( 3791919 )
1986
39
EMG and EEG biofeedback training in the treatment of a 10-year-old hyperactive boy with a developmental reading disorder. ( 6882815 )
1983
40
Helping the youngster with a reading disorder. Exploring one problem common to education, psychology, and mental health: summary of a conference. ( 5552374 )
1971
41
Problems in relating visual function to reading disorder. ( 5267181 )
1970
42
Linear dyslexia. A new form of reading disorder. ( 14424629 )
1959

Variations for Reading Disorder

Expression for Reading Disorder

Search GEO for disease gene expression data for Reading Disorder.

Pathways for Reading Disorder

GO Terms for Reading Disorder

Cellular components related to Reading Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.02 CNTNAP2 DCDC2 DOCK4 RIPOR2 ROBO1
2 stereocilium GO:0032420 8.96 DOCK4 RIPOR2

Biological processes related to Reading Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.46 DCDC2 DNAAF4 KIAA0319 ROBO1
2 neuron migration GO:0001764 9.13 DCDC2 DNAAF4 KIAA0319
3 vocal learning GO:0042297 8.62 CNTNAP2 FOXP2

Sources for Reading Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....